Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.

Maritime Neurology30 enrolled

Overview

To evaluate a Novel infusion protocol in MS patients treated with Alemtuzumab

This observational study will evaluate and anaylse primary data investigating the effects of a novel peri-infusion regimen in MS patients in a Candian clinical setting infused with Alemtuzumab. This observational study has been developed by a Canadian neurologist with the intent to treat MS patients receiving Alemtuzumab in order to mitigate infusion associated reactions (safety) by utilizing an alternative peri-infusion protocol which is a deviation from the recommendation in the Canadian Product Monograph. All the patients' recruited for this observational study were informed and consented for this novel peri-infusion regimen and were clinically followed by the neurologist for the two Alemtuzumab infusion cycles and for any subsequent Alemtuzumab infusions for potential mitigation of infusion associated reactions associated with Alemtuzumab.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis

Interventions

Alemtuzumab InjectionDRUG

This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion. Premedication with 50 mg of prednisone orally for 5 days before the infusion. During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion. Post Infusion Medication Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion. Post-medication with 50 mg of prednisone orally for 5 days after the infusion. Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patient s treated with Alemtuzumab as per canadian label - Exclusion Criteria: Contraindication to Alemtuzumab \-

Locations (1)

Maritime Neurology

Halifax, Nova Scotia, Canada

Outcomes

Primary Outcomes

Number and type of adverse events in Novel versus standard infusion protocol

This will include Changes In T,BP, R , during infusion, Need for extended observation, additional medication required or Neurological complications within 7 days of infusion , including headache, worsening of MS as measured by EDSS and peri-infusion infections.

Time frame: 2016-2020

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.